In full concordance, Galectin-1 expression was also significantly increased in A375 and SK-MEL-28 melanoma cells that developed resistance in culture upon prolonged treatment with escalating concentrations of the BRAF inhibitor PLX-4720 (Figure S1C and Figure 1A), thus recapitulating the process occurring in patients. Here, BRAF is linked to melanoma.